A Phase 2 Study of AFM13 Plus AB-101 To Treat Hodgkin Lymphoma and Peripheral T-Cell Lymphoma


Full Title

A Phase 2, Open-Label, Multi-Center Study of Innate Cell Engager AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Subjects with Recurrent or Refractory Hodgkin Lymphoma and CD30-Positive Peripheral T-Cell Lymphoma (LuminICE-203)


Researchers are assessing two new drugs given together to treat lymphoma. The people in this study have Hodgkin lymphoma or peripheral T-cell lymphoma (PTCL) that keeps growing or came back after treatment. In addition, their cancer cells make a protein called CD30.

AFM13 attaches to the CD30 protein and makes the immune system recognize and destroy cancer cells. AB-101 is a cellular therapy made in a lab using natural killer cells (NK cells) from healthy donors. NK cells are part of the immune system. They fight infections and cancer.

If you join this study, you will get AFM13 and AB-101. You will get cyclophosphamide and fludarabine first to prepare your body for the treatment. You will also get a low dose of interleukin-2 (IL-2), which helps NK cells work better. The treatments are given intravenously (by vein), except for IL-2, which is given as an injection.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have Hodgkin lymphoma or PTCL that came back or keeps growing after prior treatment. If you have Hodgkin lymphoma, you must have already had brentuximab vedotin. If you have PTCL, you must have had brentuximab vedotin or were unable to receive this drug.
  • Have cancer cells that make CD30.
  • Have completed previous treatment at least 3 weeks before getting the study drugs.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Alison Moskowitz’s office at 646-608-3726.




Phase II (phase 2)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID